Connect with us

Uncategorized

Best biotech stocks to buy in 2023

Innovation continues to drive the broader healthcare market, and the best biotech…
The post Best biotech stocks to buy in 2023 appeared first on The…

Published

9 months ago

on

Innovation continues to drive the broader healthcare market, and the best biotech stocks are at the forefront of new developments and therapies to treat a wide range of conditions. 

Just like technology, biotechnology is constantly evolving, which includes the development of personalized medicine and an uptick in orphan drug formulations. 

With that in mind, here are the best biotech stocks of 2023 that are poised for future growth. 

But first — before we dive into the picks, we will first provide a brief overview of the biotechnology market and what investors should know. 

What is biotechnology? 

In simple terms, biotechnology uses living organisms and biological systems for developing medical products. 

With that in mind, biotechnology products are intended to prevent, treat, or even cure diseases and have been known to treat everything from cancers, blood disorders and cardiovascular diseases to hepatitis B, diabetes, bacterial infections and, of course, COVID-19 vaccines, among others. 

The biotech market has especially been transformative in recent years thanks to recent innovations such as: 

biosensors, which have capabilities of tracking blood pressure, pulse, breathing and body temperature.  3D bioprinting, which is gaining notoriety by having the potential to develop everything from drugs and pills to human organs.  bioplastics, which are organic materials that can biodegrade over time.  gene editing, which alters a living organism by inserting, replacing, or entirely deleting a DNA sequence, for example hereditary illness such as Multiple Sclerosis. 

When it comes to COVID-19 vaccines, the best biotech stocks all around the world implemented their best efforts to get treatments out the door as quickly and as safely as possible.  

Following the pandemic that disrupted the world in March 2020, the rush to get vaccines to combat the disease became urgent.  

By the end of 2020, the first vaccine was administered on December 8, and by June 2022 there were over 1,500 drugs and vaccines targeting COVID-19.  

Through continued advancements, investing in the best biotech stocks has never been more interesting as innovative products continue to enter the market. 

How to invest in the best biotech stocks 

The best biotech stocks have the potential to bring investors big returns if things go according to plan — for example, if a product is considered effective and safe with no adverse side effects or if a massive breakthrough is made. 

Biotech giant Moderna (NASDAQ:MRNA) was the second-ranked company with 12 vaccines targeting COVID-19. They are a great depiction of the impact new drug development can have on a stock, at points Moderna was trading at almost $500 a share during the volatility of the pandemic. 

While someof the best biotech stocks might have massive share price increases following breakthroughs, the exact opposite can happen if something does not go according to plan — if a clinical trial does not go as expected or products do not meet their safety endpoints, among other things. 

That being said, many of the best biotech stocks may have products that never actually make it to the market due to strict regulations from the US Food and Drug Administration (FDA) or Health Canada. 

The FDA is the regulatory agency in the United States that approves the development and regulation of a wide range of products These include vaccines, prescription drugs, allergenics, cellular and gene therapy products and, of course, so much more. 

In Canada, the process is somewhat similar. The best biotech stocks are required to prove their products are safe and effective before being approved for the market. 

When it comes to both regulatory approvals in both countries, the process can be long and oftentimes frustrating for both companies and investors, but the payoff can be worth it. 

Like with all investing, investors need to be mindful of the best biotech stocks they are investing in, which is where help from biotech analysts, investment firms, or stock analysts can come in handy. Websites like Stockhouse.com include discussion boards alongside their research tools so you can communicate with existing shareholders and leverage the knowledge of peers looking to invest or share insight on their findings.  

Best biotech stocks to invest in 

There are several options when it comes to investing in the best biotech stocks, and perhaps one of the safest ways to do so is through exchange-traded funds (ETFs). 

ETFs are similar to mutual funds but can be traded over the course of a day similar to stocks. An ETF is a secured investment opportunity that focuses on a single commodity or sector. 

Putting it simply, rather than investing in a single company, ETFs provide investors with exposure to an industry — like biotech — and come with fewer risks because they are low-cost and can increase portfolio diversification. 

According to ETFDB.com, there are over 20 biotechnology ETFs for investors to choose from. The top three, with assets and previous closing prices as of May 27, 2023, are: 

iShares Biotechnology ETF (IBB), which has over $7.87 billion in assets and a previous closing price of $127.09. The index tracks biotechnology and pharmaceutical companies on the NASDAQ;  SPDR Biotech ETF (XBI), which has $6.53 billion in assets and a previous closing price of $84.31. The SPRD Biotech ETF tracks the biotechnology market segment of the S&P Total Market Index;  ARK Genomic Revolution ETF (ARKG), which has over $2 billion in assets and a closing price of $31.69. This ETF seeks long-term growth capital and tracks companies involved in CRISPR, targeted therapeutics, bioinformatics, and molecular diagnostics, among others. 

Of course, investors can always find the best biotech stocks to add to their portfolio. In Canada, the top three performing best biotech stocks with market caps between $10 million and $2 trillion year-to-date according to data from TradingView.com are: 

BriaCell Therapeutics (TSX.BTC) Market cap C$123.68 million; year-to-date increase: 31.30 per cent; current share price $7.97 

BriaCell Therapeutics is a biotechnology company focused on immuno-oncology and is developing targeted and safe treatments for cancer. The company’s lead drug candidate is Bria-IMT, which was designed to treat advanced breast cancer for patients who have not responded to previous chemotherapies. 

Cardiol Therapeutics (TSX:CRDL) Market cap $58.28 million; year-to-date increase: 26.39 per cent; current share price $0.91 

Cardiol Therapeutics is a life sciences company focused on its lead drug candidate CardiolRx, which is being used to treat rare heart diseases. The company is also developing CRD-38, a novel drug intended to treat heart failure. 

Sernova Corp. (TSX:SVA) Market cap: $254.80 million; year-to-date increase: 2.44 per cent; current share price: $0.84 

Sernova Corp. is a clinical-stage company developing products to treat chronic and debilitating diseases. Sernova is currently focused on its proprietary Cell Pouch and associated technologies that include immune-protected therapeutic cells. 

Biotechnology outlook 

The last few years have not been easy for the market with clinical trial and regulatory setbacks, high research and development costs and loss of patents, among others. 

But these sorts of hiccups are not solely restricted to the biotech industry alone because every industry fluctuates at one point or another due to the economy or political uncertainty. 

Now that we are nearing the halfway mark of 2023, the biotechnology market — and in turn the best biotech stocks — are poised for exceptional growth in the coming years. 

In 2020, it is estimated the market was valued at US$852.88 million and is projected to grow at a compound annual growth rate of 17.83 per cent between the forecast period 2021 to 2030 to reach $3.44 trillion. 

Fueling that growth will be government policies, the launch of new products and continued investment in the biotechnology sector. 

As such, the best biotech stocks will be key to watch for in the coming years as the market ramps up and innovative products continue to enter the market. 

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here. 

The post Best biotech stocks to buy in 2023 appeared first on The Market Herald Canada.

Read More

Related Topics:
Continue Reading

Uncategorized

Aging at AACR Annual Meeting 2024

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging…

Published

9 hours ago

on

March 11, 2024

By

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Aging is one of the most prominent journals published by Impact Journals. 

Credit: Impact Journals

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Aging is one of the most prominent journals published by Impact Journals. 

Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5-10 at the San Diego Convention Center in San Diego, California. This year, the AACR meeting theme is “Inspiring Science • Fueling Progress • Revolutionizing Care.”

Visit booth #4159 at the AACR Annual Meeting 2024 to connect with members of the Aging team.

About Aging-US:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed and archived by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Aging X
  • Aging Facebook
  • Aging Instagram
  • Aging YouTube
  • Aging LinkedIn
  • Aging SoundCloud
  • Aging Pinterest
  • Aging Reddit

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

Read More

Continue Reading

Uncategorized

NY Fed Finds Medium, Long-Term Inflation Expectations Jump Amid Surge In Stock Market Optimism

NY Fed Finds Medium, Long-Term Inflation Expectations Jump Amid Surge In Stock Market Optimism

One month after the inflation outlook tracked…

Published

13 hours ago

on

March 11, 2024

By

NY Fed Finds Medium, Long-Term Inflation Expectations Jump Amid Surge In Stock Market Optimism

One month after the inflation outlook tracked by the NY Fed Consumer Survey extended their late 2023 slide, with 3Y inflation expectations in January sliding to a record low 2.4% (from 2.6% in December), even as 1 and 5Y inflation forecasts remained flat, moments ago the NY Fed reported that in February there was a sharp rebound in longer-term inflation expectations, rising to 2.7% from 2.4% at the three-year ahead horizon, and jumping to 2.9% from 2.5% at the five-year ahead horizon, while the 1Y inflation outlook was flat for the 3rd month in a row, stuck at 3.0%. 

The increases in both the three-year ahead and five-year ahead measures were most pronounced for respondents with at most high school degrees (in other words, the "really smart folks" are expecting deflation soon). The survey’s measure of disagreement across respondents (the difference between the 75th and 25th percentile of inflation expectations) decreased at all horizons, while the median inflation uncertainty—or the uncertainty expressed regarding future inflation outcomes—declined at the one- and three-year ahead horizons and remained unchanged at the five-year ahead horizon.

Going down the survey, we find that the median year-ahead expected price changes increased by 0.1 percentage point to 4.3% for gas; decreased by 1.8 percentage points to 6.8% for the cost of medical care (its lowest reading since September 2020); decreased by 0.1 percentage point to 5.8% for the cost of a college education; and surprisingly decreased by 0.3 percentage point for rent to 6.1% (its lowest reading since December 2020), and remained flat for food at 4.9%.

We find the rent expectations surprising because it is happening just asking rents are rising across the country.

At the same time as consumers erroneously saw sharply lower rents, median home price growth expectations remained unchanged for the fifth consecutive month at 3.0%.

Turning to the labor market, the survey found that the average perceived likelihood of voluntary and involuntary job separations increased, while the perceived likelihood of finding a job (in the event of a job loss) declined. "The mean probability of leaving one’s job voluntarily in the next 12 months also increased, by 1.8 percentage points to 19.5%."

Mean unemployment expectations - or the mean probability that the U.S. unemployment rate will be higher one year from now - decreased by 1.1 percentage points to 36.1%, the lowest reading since February 2022. Additionally, the median one-year-ahead expected earnings growth was unchanged at 2.8%, remaining slightly below its 12-month trailing average of 2.9%.

Turning to household finance, we find the following:

  • The median expected growth in household income remained unchanged at 3.1%. The series has been moving within a narrow range of 2.9% to 3.3% since January 2023, and remains above the February 2020 pre-pandemic level of 2.7%.
  • Median household spending growth expectations increased by 0.2 percentage point to 5.2%. The increase was driven by respondents with a high school degree or less.
  • Median year-ahead expected growth in government debt increased to 9.3% from 8.9%.
  • The mean perceived probability that the average interest rate on saving accounts will be higher in 12 months increased by 0.6 percentage point to 26.1%, remaining below its 12-month trailing average of 30%.
  • Perceptions about households’ current financial situations deteriorated somewhat with fewer respondents reporting being better off than a year ago. Year-ahead expectations also deteriorated marginally with a smaller share of respondents expecting to be better off and a slightly larger share of respondents expecting to be worse off a year from now.
  • The mean perceived probability that U.S. stock prices will be higher 12 months from now increased by 1.4 percentage point to 38.9%.
  • At the same time, perceptions and expectations about credit access turned less optimistic: "Perceptions of credit access compared to a year ago deteriorated with a larger share of respondents reporting tighter conditions and a smaller share reporting looser conditions compared to a year ago."

Also, a smaller percentage of consumers, 11.45% vs 12.14% in prior month, expect to not be able to make minimum debt payment over the next three months

Last, and perhaps most humorous, is the now traditional cognitive dissonance one observes with these polls, because at a time when long-term inflation expectations jumped, which clearly suggests that financial conditions will need to be tightened, the number of respondents expecting higher stock prices one year from today jumped to the highest since November 2021... which incidentally is just when the market topped out during the last cycle before suffering a painful bear market.

Tyler Durden Mon, 03/11/2024 - 12:40

Read More

Continue Reading

Uncategorized

Homes listed for sale in early June sell for $7,700 more

New Zillow research suggests the spring home shopping season may see a second wave this summer if mortgage rates fall
The post Homes listed for sale in…

Published

21 hours ago

on

March 11, 2024

By

  • A Zillow analysis of 2023 home sales finds homes listed in the first two weeks of June sold for 2.3% more. 
  • The best time to list a home for sale is a month later than it was in 2019, likely driven by mortgage rates.
  • The best time to list can be as early as the second half of February in San Francisco, and as late as the first half of July in New York and Philadelphia. 

Spring home sellers looking to maximize their sale price may want to wait it out and list their home for sale in the first half of June. A new Zillow® analysis of 2023 sales found that homes listed in the first two weeks of June sold for 2.3% more, a $7,700 boost on a typical U.S. home.  

The best time to list consistently had been early May in the years leading up to the pandemic. The shift to June suggests mortgage rates are strongly influencing demand on top of the usual seasonality that brings buyers to the market in the spring. This home-shopping season is poised to follow a similar pattern as that in 2023, with the potential for a second wave if the Federal Reserve lowers interest rates midyear or later. 

The 2.3% sale price premium registered last June followed the first spring in more than 15 years with mortgage rates over 6% on a 30-year fixed-rate loan. The high rates put home buyers on the back foot, and as rates continued upward through May, they were still reassessing and less likely to bid boldly. In June, however, rates pulled back a little from 6.79% to 6.67%, which likely presented an opportunity for determined buyers heading into summer. More buyers understood their market position and could afford to transact, boosting competition and sale prices.

The old logic was that sellers could earn a premium by listing in late spring, when search activity hit its peak. Now, with persistently low inventory, mortgage rate fluctuations make their own seasonality. First-time home buyers who are on the edge of qualifying for a home loan may dip in and out of the market, depending on what’s happening with rates. It is almost certain the Federal Reserve will push back any interest-rate cuts to mid-2024 at the earliest. If mortgage rates follow, that could bring another surge of buyers later this year.

Mortgage rates have been impacting affordability and sale prices since they began rising rapidly two years ago. In 2022, sellers nationwide saw the highest sale premium when they listed their home in late March, right before rates barreled past 5% and continued climbing. 

Zillow’s research finds the best time to list can vary widely by metropolitan area. In 2023, it was as early as the second half of February in San Francisco, and as late as the first half of July in New York. Thirty of the top 35 largest metro areas saw for-sale listings command the highest sale prices between May and early July last year. 

Zillow also found a wide range in the sale price premiums associated with homes listed during those peak periods. At the hottest time of the year in San Jose, homes sold for 5.5% more, a $88,000 boost on a typical home. Meanwhile, homes in San Antonio sold for 1.9% more during that same time period.  

 

Metropolitan Area Best Time to List Price Premium Dollar Boost
United States First half of June 2.3% $7,700
New York, NY First half of July 2.4% $15,500
Los Angeles, CA First half of May 4.1% $39,300
Chicago, IL First half of June 2.8% $8,800
Dallas, TX First half of June 2.5% $9,200
Houston, TX Second half of April 2.0% $6,200
Washington, DC Second half of June 2.2% $12,700
Philadelphia, PA First half of July 2.4% $8,200
Miami, FL First half of June 2.3% $12,900
Atlanta, GA Second half of June 2.3% $8,700
Boston, MA Second half of May 3.5% $23,600
Phoenix, AZ First half of June 3.2% $14,700
San Francisco, CA Second half of February 4.2% $50,300
Riverside, CA First half of May 2.7% $15,600
Detroit, MI First half of July 3.3% $7,900
Seattle, WA First half of June 4.3% $31,500
Minneapolis, MN Second half of May 3.7% $13,400
San Diego, CA Second half of April 3.1% $29,600
Tampa, FL Second half of June 2.1% $8,000
Denver, CO Second half of May 2.9% $16,900
Baltimore, MD First half of July 2.2% $8,200
St. Louis, MO First half of June 2.9% $7,000
Orlando, FL First half of June 2.2% $8,700
Charlotte, NC Second half of May 3.0% $11,000
San Antonio, TX First half of June 1.9% $5,400
Portland, OR Second half of April 2.6% $14,300
Sacramento, CA First half of June 3.2% $17,900
Pittsburgh, PA Second half of June 2.3% $4,700
Cincinnati, OH Second half of April 2.7% $7,500
Austin, TX Second half of May 2.8% $12,600
Las Vegas, NV First half of June 3.4% $14,600
Kansas City, MO Second half of May 2.5% $7,300
Columbus, OH Second half of June 3.3% $10,400
Indianapolis, IN First half of July 3.0% $8,100
Cleveland, OH First half of July  3.4% $7,400
San Jose, CA First half of June 5.5% $88,400

 

The post Homes listed for sale in early June sell for $7,700 more appeared first on Zillow Research.

Read More

Continue Reading

Trending